Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice

Hypertension Research

Volumn 31, Issue 5, 2008, Pages 999-1005

  Inaba, Toshihiro ^a   Yagyu, Hiroaki ^a   Itabashi, Naoki ^a   Tazoe, Fumiko ^a   Fujita, Nobuya ^a   Nagashima, Shu Ichi ^a   Okada, Koji ^a   Okazaki, Mitsuyo ^b   Furukawa, Yusuke ^a   Ishibashi, Shun ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Cholesterol; Fibrates; Lipoproteins; Receptor

Indexed keywords

ABC TRANSPORTER A1; ADIPONECTIN; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; BEZAFIBRATE; CHOLESTEROL; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN RECEPTOR; INSULIN; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA SINUS; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; FOOD INTAKE; GENE EXPRESSION; INHIBITION KINETICS; KNOCKOUT MOUSE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SYNTHESIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ANIMALS; ANTILIPEMIC AGENTS; AORTA; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; BEZAFIBRATE; BLOOD GLUCOSE; CHEMOKINE CCL2; CHOLESTEROL, HDL; DISEASE MODELS, ANIMAL; LIPIDS; LIPOPROTEIN LIPASE; LIPOPROTEINS; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, LDL; RNA, MESSENGER; TRIGLYCERIDES;

EID: 46049086958     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.999     Document Type: Article

References (44)

1. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093.
2. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 527-550.
3. Shepherd J: Mechanism of action of fibrates. Postgrad Med J 1993; 69 (Suppl 1): S34-S41.
4. Caslake MJ, Packard CJ, Gaw A, et al: Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993; 13: 702-711.
5. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al: PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15: 5336-5348.
6. Heller F, Harvengt C: Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 1983; 25: 57-63.
7. Staels B, Auwerx J: Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and alpha-fetoprotein as models. Development 1992; 115: 1035-1043.
8. Staels B, Vu-Dac N, Kosykh VA, et al: Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995; 95: 705-712.
9. Wang CS, McConathy WJ, Kloer HU, Alaupovic P: Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985; 75: 384-390.
10. Torra IP, Chinetti G, Duval C, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol 2001; 12: 245-254.
11. Staels B, Auwerx J: Regulation of apo A-I gene expression by fibrates. Atherosclerosis 1998; 137 (Suppl): S19-S23.
12. Berthou L, Saladin R, Yaqoob P, et al: Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. Eur J Biochem 1995; 232: 179-187.
13. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J: PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999; 99: 3125-3131.
14. Shu H, Wong B, Zhou G, et al: Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 2000; 267: 345-349.
15. Neve BP, Corseaux D, Chinetti G, et al: PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001; 103: 207-212.
16. Chinetti G, Griglio S, Antonucci M, et al: Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273: 25573-25580.
17. Duez H, Chao YS, Hernandez M, et al: Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 2002; 277: 48051-48057.
18. Fu T, Kashireddy P, Borensztajn J: The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. Biochem J 2003; 373: 941-947.
19. Fu T, Mukhopadhyay D, Davidson NO, Borensztajn J: The peroxisome proliferator-activated receptor alpha (PPAR-alpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions. J Biol Chem 2004; 279: 28662-28669.
20. Tordjman K, Bernal-Mizrachi C, Zemany L, et al: PPAR-alpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest 2001; 107: 1025-1034.
21. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male, postinfarction patients. Lancet 1996; 347: 849-853.
22. Group TBS: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21-27.
23. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J: Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-893.
24. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P: Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 1985; 57: 65-73.
25. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA: Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987; 68: 231-240.
26. Yagyu H, Kitamine T, Osuga J, et al: Absence of ACAT-1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia. J Biol Chem 2000; 275: 21324-21330.
27. Usui S, Hara Y, Hosaki S, Okazaki M: A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 2002; 43: 805-814.
28. Kako Y, Huang LS, Yang J, Katopodis T, Ramakrishnan R, Goldberg IJ: Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice, Effects on lipoproteins and atherosclerosis. J Lipid Res 1999; 40: 2185-2194.
29. van Vlijmen BJ, Rohlmann A, Page ST, et al: An extrahepatic receptor-associated protein-sensitive mechanism is involved in the metabolism of triglyceride-rich lipoproteins. J Biol Chem 1999; 274: 35219-35226.
30. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
31. Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245.
32. Rubins HB, Robins SJ, Collins D, et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418.
33. Keech A, Simes RJ, Barter P, et al: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
34. Li L, Beauchamp MC, Renier G: Peroxisome proliferator-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression. Atherosclerosis 2002; 165: 101-110.
35. Peters JM, Hennuyer N, Staels B, et al: Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 1997; 272: 27307-27312.
36. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-435.
37. Shimada M, Ishibashi S, Inaba T, et al: Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Proc Natl Acad Sci U S A 1996; 93: 7242-7246.
38. Yamauchi T, Kamon J, Waki H, et al: Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278: 2461-2468.
39. Okamoto Y, Kihara S, Ouchi N, et al: Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767-2770.
40. Guerre-Millo M, Gervois P, Raspe E, et al: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000; 275: 16638-16642.
41. Kim JI, Tsujino T, Fujioka Y, Saito K, Yokoyama M: Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens Res 2003; 26: 307-313.
42. Tenenbaum A, Motro M, Fisman EZ, et al: Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004; 109; 2197-2202.
43. Chinetti G, Lestavel S, Bocher V, et al: PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7: 53-58.
44. Chinetti G, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function. Curr Opin Lipidol 2003; 14: 459-468.